Loading...

Purified anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-W632_Purified_072607
Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • a-W632_Purified_072607
    Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • b-632_012105
    HEK293 cells were transfected with RelA or empty vector and 24hrs later cell extracts harvested using a 1% CHAPS lysis buffer. Extracts were resolved by non-denaturing, non-reducing electrophoresis, transferred to nitrocellulose, and probed with a 1:500 dilution purified W6/32 . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. These data document that MHC class I was upregulated in cells constitutively expressing RelA. (Data was provided by Dr. Ezra Burstein, University of Michigan Medical School, Ann Arbor, MI).
Cat # Size Price Quantity Check Availability Save
311402 100 µg 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Activ, Block, IHC-F, IP, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Blees A, et al. 2017. Nature.. 10.1038/nature24627. PubMed
  2. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  3. Wroblewska A et al. 2018. Cell. 175(4):1141-1155 . PubMed
  4. Makarkov AI, et al. 2019. NPJ Vaccines. 4:17. PubMed
  5. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
  6. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  7. Chen HC, et al. 2017. Immunol Cell Biol. 95:620. PubMed
  8. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
  9. Mirandola L, et al. 2017. Oncotarget. 8:74378. PubMed
  10. Andersen R, et al. 2018. Cancer Immunol Res. 0.404166667. PubMed
  11. Garrido C, et al. 2018. JCI Insight. 3:e120121. PubMed
  12. Abdul–Salam VB, et al. 2019. Circ Res. 124:52:00. PubMed
  13. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  14. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  15. Carlsten M, et al. 2019. Oncoimmunology. 8:e1534664. PubMed
  16. Jasmer B, et al. 2017. Oncotarget. 8:108643. PubMed
  17. Chen WT, et al. 2018. J Invest Dermatol. 138:1546. PubMed
  18. Tsuchiya N, et al. 2018. Oncoimmunology. 7:e1377872. PubMed
  19. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  20. Fitzgerald W, et al. 2018. Am J Reprod Immunol. 80:e12860. PubMed
  21. McLoughlin R, et al. 2008. J Immunol. 181:1323. PubMed
  22. Takahara M, et al. 2008. J Leukoc Biol. 83:742. PubMed
  23. Laing B, et al. 2010. J Thorac Cardiovasc Surg. 139:1402. PubMed
  24. Takeuchi M, et al. 2010. J Mol Cell Biol. 0.179861111. PubMed
  25. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  26. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  27. A A, et al. 2016. Biotechnol Bioeng. 112: 2214-27. PubMed
  28. Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed
  29. Nöll A, et al. 2017. Proc Natl Acad Sci U S A. 114: E438 - E447. PubMed
  30. Liu Y, et al. 2017. Clin Cancer Res. 23(2):514-522. PubMed
  31. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  32. Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed
  33. Pettmann J, et al. 2021. eLife. 10:00. PubMed
  34. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  35. Ruiz Cuevas MV, et al. 2021. Cell Reports. 34(10):108815. PubMed
  36. Parker R, et al. 2020. bioRxiv. . PubMed
  37. Han EX, et al. 2021. NPJ Regen Med. 6:40. PubMed
  38. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  39. Willimsky G, et al. 2021. Elife. 10:. PubMed
  40. Gañán-Gómez I, et al. 2022. Nat Med. . PubMed
  41. Chen YL, et al. 2020. J Exp Med. 217:. PubMed
  42. Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed
  43. Hsiue EH, et al. 2021. Science. 371:. PubMed
  44. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  45. Neuperger P, et al. 2021. Cancers (Basel). 14:. PubMed
  46. Sharma M, et al. 2020. Front Immunol. 11:1136. PubMed
  47. Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed
  48. Higashi S, et al. 2022. J Cell Sci. 135:. PubMed
  49. Zhu Z, et al. 2022. Front Oncol. 12:814312. PubMed
  50. Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed
  51. Chou JM, et al. 2022. Front Microbiol. 13:883597. PubMed
  52. Jimenez-Duran G, et al. 2022. Front Immunol. 13:918551. PubMed
  53. Gallen C, et al. 2022. Vaccines (Basel). 10:. PubMed
  54. Mirlashari MR, et al. 2021. Transfusion. 61:1222. PubMed
  55. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  56. Sim MJW, et al. 2022. Elife. 11: . PubMed
  57. Moon JS, et al. 2023. Nat Commun. 14:319. PubMed
  58. Khatri A, et al. 2023. JCI Insight. 8:. PubMed
  59. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
RRID
AB_314871 (BioLegend Cat. No. 311402)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org
Go To Top Version: 3    Revision Date: 09-06-2022

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account